Details

Autor(en) / Beteiligte

• Chow, James C.H.
• Lee, Anne W.M.
• Wong, Charlene H.L.
• Ng, Wai Tong
• Liu, Zhiwei
• Tay, Joshua K.
• Loh, Kwok Seng
• Pace-Asciak, Pia
• Cohen, Oded
• Corry, June
• Rodrigo, Juan Pablo
• Tsang, Raymond K.Y.
• Lopez, Fernando
• Saba, Nabil F.
• de Bree, Remco
• Ferlito, Alfio

Titel

Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review

Ist Teil von

• Oral oncology, 2022-10, Vol.133, p.106031-106031, Article 106031

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •The systematic review summarizes the role of EBV-directed familial NPC screening.•Ten cross-sectional studies (n = 7436) and three cohort studies (n = 4306) were included.•EBV positivity rates were high in family members of NPC patients.•Family members of NPC patients who are EBV-positive had high risks of developing NPC.•Familial NPC screening with EBV serology may be warranted in endemic areas. Evidence to support Epstein-Barr virus (EBV)-directed population nasopharyngeal carcinoma (NPC) screening has been growing. Familial aggregation is a well-recognized phenomenon in endemic regions. This systematic review summarizes the role of EBV-directed screening in individuals with a positive family history (FH+) of NPC. We searched four electronic databases from their inception to October 2021. We included studies on individuals with FH+ of NPC who had undergone EBV-directed investigations, with no restriction in the testing methods or analytic techniques. The primary and secondary outcomes were EBV positivity rates and NPC incidence rates, respectively. Meta-analyses were performed using the random-effect model. Ten cross-sectional studies (n = 7436) and three cohort studies (n = 4306) were included. The pooled relative risk (RR) of EBV positivity between individuals with and without FH+ of NPC were 2.79 (95 % CI 1.37–5.68, p = 0.005) for viral capsid antigen (VCA) IgA, 3.09 (95 % CI 0.65–14.83, p = 0.16) for Epstein-Barr nuclear antigen (EBNA1) IgA, and 1.76 (95 % CI 1.04–2.96, p = 0.03) for combined EBNA1/VCA IgA. In the three cohort studies, the NPC incidence rates ranged from 90.2 to 266 per 100 000 person-years with high proportions of early-stage diseases. FH+ individuals who were EBV-positive had a 2.5 to 30.7-fold risk of NPC development compared to their EBV-negative counterparts. Family members of NPC patients had significantly higher EBV positivity rates than the general population. FH+ individuals who are EBV-positive had high risks of developing NPC. Familial screening using EBV serology may facilitate early NPC detection in endemic areas.